Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

NCT05457582 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT05457582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Not applicable
Overall status
Active, not recruiting
Start date
March 30, 2023
Completion date
December 30, 2030
Enrollment
1,212 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, cardiovascular events, hyperlipidemias, percutaneous coronary intervention